about
Surface Plasmon Resonance Analysis Shows an IgG-Isotype-Specific Defect in ABO Blood Group Antibody Formation in Patients with Common Variable ImmunodeficiencyBlockade of HLA Antibody-Triggered Classical Complement Activation in Sera from Subjects Dosed with the Anti-C1s Monoclonal Antibody TNT009 - Results from a Randomized First-in-Human Phase 1 Trial.Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trialGenotypic diversity of complement component C4 does not predict kidney transplant outcomeIg-like transcript 4 as a cellular receptor for soluble complement fragment C4d.Antibodies, isotypes and complement in allograft rejection.Transplantation of the broadly sensitized patient: what are the options?Detection of alloantibody-mediated complement activation: A diagnostic advance in monitoring kidney transplant rejection?Complement inhibition as potential new therapy for antibody-mediated rejection.Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.Flow cytometry based detection of HLA alloantibody mediated classical complement activation.Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes.Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation.Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.C4d deposits in renal allografts are associated with inferior graft outcome.Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection.Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes.Risk factors for capillary C4d deposition in kidney allografts: evaluation of a large study cohort.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.Prospects and limitations of post-transplantation alloantibody detection in renal transplantation.[C4d]FlowPRA screening--a specific assay for selective detection of complement-activating anti-HLA alloantibodies.Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation.ABO antibody and complement depletion by immunoadsorption combined with membrane filtration--a randomized, controlled, cross-over trial.Modified solid-phase alloantibody detection for improved crossmatch prediction.Prevalence and qualitative properties of circulating anti-human leukocyte antigen alloantibodies after pregnancy: no association with unexplained recurrent miscarriageCD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activationRescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.Metabolism of activated complement component C3 is mediated by the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptorImmunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trialDeterminants of the complement-fixing ability of recipient presensitization against HLA antigensAnti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorptionSignificance of peritubular capillary, glomerular, and arteriolar C4d staining patterns in paraffin sections of early kidney transplant biopsiesPivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipientsABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorptionC4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection
P50
Q28393419-D380761E-973F-427E-86FC-96FC828CCDFAQ30491939-937D59AA-CE0C-48C9-A31E-B8216B9DE553Q33584895-94FDB672-B852-4087-9EDE-AB3570DEA440Q34534928-B3E967E9-11D7-4566-99FA-960A5933BAF9Q35871751-08C0C899-978E-4ACE-86EE-F1950AF0859CQ37236978-26767EC2-409F-4E64-8024-A891A6755A19Q37942453-9EDFD540-1947-46A3-B5AA-1208ECA8A9B8Q38539302-A8EF7477-7B7E-444C-894D-7B4BC1B85E2DQ38609238-C3FABCAB-497E-4B19-9D52-974FE8674474Q40014764-0565595E-72E7-455B-82FE-EFC4C1AB9A69Q40597066-95585755-B9E1-4C45-B049-C1CD54B3AE2BQ40635443-73B89CBF-66C9-4FC6-A3F3-E0D63206335BQ40779288-8A211287-2EAD-4BA0-8E42-54FFEA64E664Q42359412-59B64395-EE83-4328-9CDC-9AA7190C52C8Q42670153-89E45442-9AE0-4E05-A1C8-F31820BF3472Q42731771-CFA18B86-ABDE-43E1-9A62-835D573700F2Q42872851-235B0252-D2B3-4A84-B92A-28397079A204Q43119566-E2391288-294D-45CE-80B3-8D2D937E915CQ43552918-DD5298A6-7380-4994-B739-EB04ADFBA347Q43747982-1B3C797E-ED99-45CC-8591-D3C40F252508Q44598524-76427BA4-54FE-42C3-BCDF-7E92231F132DQ45022068-FBBB2A23-B29F-451C-8C64-832E6EC0BD62Q47292306-1A9D46EB-2CB7-4427-BA0E-E9F45A5A9F76Q47694251-54F91E1C-9FA0-4697-B34E-8F74C811ACE4Q47989409-72EBA5E0-47DD-4851-8A51-B87B50D68CBCQ51443894-36FEEADC-A60D-45D6-A4DD-81F03F6560A4Q51738292-012D8A2A-51EC-4F43-BE3E-424DF0664B25Q51762531-663E7702-B2B9-4F4A-BA8B-2F49FAADED20Q53139288-14C0F1DF-DBD7-4A51-AF58-28EAA6775E76Q61840766-5ADB810C-5BD0-46B3-850C-3877FCA32F14Q64068228-10C4946C-99A9-424F-B863-F21D54B880C7Q64982205-64460C29-CEC5-48ED-AB15-1A0C68EBAAB3Q73297617-A9D7EBCD-7DB2-424B-A17F-209C73018F8DQ79364646-AF4F7D1E-71B2-4AFF-B678-628A360DC5ABQ80112086-034EF8D2-4C87-49D8-817A-F44864838C95Q82521458-28470DC3-C5F7-4B69-AAFE-3FA3A4668654Q82715812-28E2D105-E649-4B34-AD12-BF5068065817Q83149390-067C8E76-FF44-47EB-A712-CFCB6CC2060FQ83552932-120F1407-86D2-4BD1-8386-64457F4684BAQ84069012-2E24B0A8-AA36-4117-9110-C1131BE429BD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Markus Wahrmann
@ast
Markus Wahrmann
@en
Markus Wahrmann
@es
Markus Wahrmann
@nl
Markus Wahrmann
@sl
type
label
Markus Wahrmann
@ast
Markus Wahrmann
@en
Markus Wahrmann
@es
Markus Wahrmann
@nl
Markus Wahrmann
@sl
prefLabel
Markus Wahrmann
@ast
Markus Wahrmann
@en
Markus Wahrmann
@es
Markus Wahrmann
@nl
Markus Wahrmann
@sl
P106
P21
P2798
P31
P496
0000-0002-1301-8694